TriSalus Life Sciences Reports Strong Revenue Growth Amidst Increased Losses, Going Concern Warning, and Material Weakness

summarizeSummary

TriSalus Life Sciences reported strong 53.4% revenue growth in 2025, but also disclosed increased net losses, a going concern warning, and an unremediated material weakness in internal controls, despite a recent $42.6 million public offering.

check_boxKey Events

• Strong Revenue Growth in Device Business

  TriNav device revenue increased by 53.4% to $45.2 million in 2025, driven by increased unit sales and new product launches (TriNav FLX and TriNav XP).

• Increased Net Loss and Going Concern Warning

  The company's net loss widened to $39.2 million in 2025 from $30.0 million in 2024. Management explicitly states that its continuation as a going concern is dependent on obtaining additional capital.

• Unremediated Material Weakness in Internal Controls

  As of December 31, 2025, the company has an unremediated material weakness in its internal control over financial reporting related to accounting for significant transactions.

• Successful Public Offering for Liquidity

  The company successfully closed a public offering on February 23, 2026, raising approximately $42.6 million in net proceeds, providing critical capital following the fiscal year end.

auto_awesomeAnalysis

TriSalus Life Sciences' annual report for 2025 reveals a mixed financial picture. While the company achieved significant revenue growth of 53.4% to $45.2 million, its net loss widened to $39.2 million. The filing includes a going concern warning, indicating the company's dependence on future capital raises. A notable concern is the disclosure of an unremediated material weakness in internal control over financial reporting related to accounting for significant transactions. This 10-K confirms the recent public offering that raised $42.6 million in net proceeds, which was previously announced on February 20, 2026, and provides crucial liquidity. However, the company is seeking partners for its nelitolimod drug development due to "excessive costs of capital," highlighting ongoing funding challenges for its therapeutic pipeline.